Tweet
Investment analysts at Stifel Nicolaus initiated coverage on shares of Zogenix (NASDAQ:ZGNX) in a report released on Wednesday. The brokerage set a "buy" rating and a $69.00 price target on the stock. Stifel Nicolaus' price target points to a potential upside of 43.60% from the company's previous close.
Several other analysts also recently weighed in on the company. Mizuho lifted their price objective on Zogenix to $69.00 and gave the company a "positive" rating in a report on Thursday, July 12th. BidaskClub upgraded Zogenix from a "buy" rating to a "strong-buy" rating in a report on Friday, June 1st. Empire boosted their target price on shares of Zogenix from $57.00 to $66.00 and gave the stock a "buy" rating in a report on Tuesday, July 31st. Zacks Investment Research upgraded shares of Zogenix from a "sell" rating to a "hold" rating in a report on Wednesday, June 6th. Finally, ValuEngine upgraded shares of Zogenix from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of "Buy" and a consensus target price of $60.67. Get Zogenix alerts:
ZGNX stock opened at $48.05 on Wednesday. The stock has a market capitalization of $1.80 billion, a P/E ratio of -11.95 and a beta of 2.13. Zogenix has a 1-year low of $11.40 and a 1-year high of $62.75. Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Monday, August 6th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.06. During the same period in the prior year, the company earned ($0.90) earnings per share. research analysts anticipate that Zogenix will post -3.72 EPS for the current fiscal year.
In other Zogenix news, EVP Gail M. Farfel sold 7,000 shares of the business's stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $52.62, for a total value of $368,340.00. Following the completion of the transaction, the executive vice president now directly owns 14,143 shares in the company, valued at $744,204.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website . Also, EVP Gail M. Farfel sold 5,118 shares of the business's stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $230,310.00. The disclosure for this sale can be found here . Insiders own 4.60% of the company's stock.
A number of institutional investors have recently made changes to their positions in ZGNX. BlueMountain Capital Management LLC purchased a new stake in shares of Zogenix during the second quarter worth about $104,000. SG Americas Securities LLC purchased a new stake in shares of Zogenix during the first quarter worth about $100,000. Meadow Creek Investment Management LLC purchased a new stake in shares of Zogenix during the first quarter worth about $192,000. Amalgamated Bank purchased a new stake in shares of Zogenix during the second quarter worth about $232,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Zogenix during the second quarter worth about $239,000.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome